Page last updated: 2024-12-07

albizziin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Albizziin is a non-protein amino acid that was first isolated from the plant Albizzia saman. It is a potent inhibitor of glutamate decarboxylase, the enzyme responsible for converting glutamate to GABA. This inhibition leads to increased levels of glutamate in the brain, which can have neurotoxic effects. Albizziin has also been shown to have anti-inflammatory and anti-tumor activity. Due to its potent biological activity, albizziin has been studied for its potential therapeutic applications in treating neurological disorders, cancer, and inflammation. The synthesis of albizziin involves a complex multi-step process that starts from the amino acid L-glutamine. Albizziin is an interesting molecule due to its unique structure and its potent biological activity. It is a promising target for the development of new drugs for the treatment of a wide range of diseases.'

albizziin: RN given refers to parent cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID92891
CHEBI ID6173
SCHEMBL ID690347
MeSH IDM0049023

Synonyms (55)

Synonym
nsc-132089
albizzine
l-albizziin
l-alanine, 3-[(aminocarbonyl)amino]-
l-2-amino-3-ureidopropionic acid
C08264
albizziin
l-albizziine
1483-07-4
A-4650
zinc01531037
(2s)-2-amino-3-(carbamoylamino)propanoic acid
A808754 ,
(s)-2-amino-3-ureidopropanoicacid
AKOS006237907
3-ureido-l-alanin
l-alanine, 3-((aminocarbonyl)amino)-
albizziin (van)
nsc 132089
einecs 216-046-1
l-beta-ureidoalanine
rw59as48cr ,
unii-rw59as48cr
l-(-)-2-amino-3-ureidopropionic acid
propionic acid, 2-amino-3-ureido-, l-
nsc 407273
albizziin [mi]
3-((aminocarbonyl)amino)-l-alanine
SCHEMBL690347
CHEBI:6173
(2s)-2-amino-3-ureido-propanoic acid
3-[(aminocarbonyl)amino]alanine #
GZYFIMLSHBLMKF-REOHCLBHSA-N
(2s)-2-ammonio-3-(carbamoylamino)propanoate
(2s)-3-(aminocarbonylamino)-2-azaniumyl-propanoate
c4h9n3o3
albizziin (h-dap(conh2)-oh)
mfcd00007952
l-(-)2-amino-3-ureidopropionic acid
h-beta-(ureido)-ala-oh
AS-63003
C90278
albizziin, aldrichcpr
h--((aminocarbonyl)amino)-ala-oh;h-dap(carbamoyl)-oh
(s)-2-amino-3-ureidopropanoic acid
Q27107112
AMY22571
HY-121167
butyl 4-?hydroxybenzoate
(butyl paraben)
DTXSID501318659
EN300-7026825
CS-0079579
nsc823850
nsc-823850
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
non-proteinogenic L-alpha-amino acidAny L-alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (57.14)18.7374
1990's3 (42.86)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.39 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]